BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37595020)

  • 1. Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors.
    Jian L; Zscherp R; Beutling U; Shen X; Xu S; Zhang X; Brönstrup M; Klahn P; Sun Q
    J Med Chem; 2023 Sep; 66(17):11940-11950. PubMed ID: 37595020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Hidden Pocket beneath the NES Groove by Novel Noncovalent CRM1 Inhibitors.
    Li C; Zhang Q; Huang W; Huang L; Long Q; Lei Y; Jia D; Yang S; Yang Y; Zhang X; Sun Q
    J Med Chem; 2023 Dec; 66(24):17044-17058. PubMed ID: 38105606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching for Novel Noncovalent Nuclear Export Inhibitors through a Drug Repurposing Approach.
    Huang W; Wang JX; Shen X; Lei Y; Chen X; Jia D; Zhang X; Sun Q
    J Med Chem; 2023 Jan; 66(2):1574-1582. PubMed ID: 36622814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1-mediated nuclear export.
    Jimenez L; Mayoral-Varo V; Amenábar C; Ortega J; Sequeira JGN; Machuqueiro M; Mourato C; Silvestri R; Angeli A; Carta F; Supuran CT; Megías D; Ferreira BI; Link W
    Traffic; 2022 Dec; 23(12):587-599. PubMed ID: 36353954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
    von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
    Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
    J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
    Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
    Liu S; Qiao W; Sun Q; Luo Y
    J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
    Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecule Inhibitors of CRM1.
    Ferreira BI; Cautain B; Grenho I; Link W
    Front Pharmacol; 2020; 11():625. PubMed ID: 32574233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
    Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
    J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallization of Nuclear Export Signals or Small-Molecule Inhibitors Bound to Nuclear Exporter CRM1.
    Fung HYJ; Chook YM
    Methods Mol Biol; 2022; 2502():285-297. PubMed ID: 35412246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.